These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25076428)

  • 1. Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
    Ribeiro MN; Pimentel MI; Schubach Ade O; Oliveira Rde V; Teixeira JL; Leite MP; Fonseca M; Santos GP; Salgueiro MM; Ferreira e Vasconcellos Ede C; Lyra MR; Saheki MN; Valete-Rosalino CM
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):291-6. PubMed ID: 25076428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
    Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
    Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).
    Vasconcellos Ede C; Pimentel MI; Schubach Ade O; de Oliveira Rde V; Azeredo-Coutinho RB; Silva Fda C; Salgueiro Mde M; Moreira JS; Madeira Mde F; Baptista C; Valete-Rosalino CM
    Am J Trop Med Hyg; 2012 Aug; 87(2):257-60. PubMed ID: 22855754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
    López L; Robayo M; Vargas M; Vélez ID
    Trials; 2012 May; 13():58. PubMed ID: 22594858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
    Aste N; Pau M; Ferreli C; Biggio P
    Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
    Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.
    Khatami A; Talaee R; Rahshenas M; Khamesipour A; Mehryan P; Tehrani S; Dowlati Y; Firooz A
    PLoS One; 2013; 8(6):e66123. PubMed ID: 23826087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 9. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
    Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis.
    Shanehsaz SM; Ishkhanian S
    Int J Dermatol; 2015 Jul; 54(7):834-8. PubMed ID: 26108265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ; Aminjavaheri M
    Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate.
    Schubach Ade O; Marzochi KB; Moreira JS; Schubach TM; Araújo ML; Vale AC; Passos SR; Marzochi MC
    Rev Soc Bras Med Trop; 2005; 38(3):213-7. PubMed ID: 15895170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
    Momeni AZ; Reiszadae MR; Aminjavaheri M
    Int J Dermatol; 2002 Jul; 41(7):441-3. PubMed ID: 12121563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran.
    Zerehsaz F; Salmanpour R; Handjani F; Ardehali S; Panjehshahin MR; Tabei SZ; Tabatabaee HR
    Int J Dermatol; 1999 Aug; 38(8):610-2. PubMed ID: 10487453
    [No Abstract]   [Full Text] [Related]  

  • 16. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
    Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: A randomized controlled trial.
    Lago T; Peixoto F; Mambelli F; Carvalho LP; Guimarães LH; Carvalho AM; Cardoso L; Machado PRL; Scott P; Lago J; Andrade JM; Fahel JS; Oliveira SC; Carvalho EM
    Int J Infect Dis; 2024 Oct; 147():107206. PubMed ID: 39147194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimonial treatments of leishmaniasis].
    Oliveira Neto MP
    Rev Soc Bras Med Trop; 2005; 38(5):446. PubMed ID: 16172767
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
    Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.